Capstone Investment Advisors’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $872K | Buy |
+6,254
| New | +$876K | ﹤0.01% | 906 |
|
|
2025
Q4 | – | Sell |
-16,452
| Closed | -$2M | – | 1772 |
|
|
2025
Q3 | $1.83M | Buy |
16,452
+9,848
| +149% | +$1.12M | ﹤0.01% | 791 |
|
|
2025
Q2 | $732K | Buy |
+6,604
| New | +$703K | ﹤0.01% | 965 |
|
|
2025
Q1 | – | Sell |
-19,692
| Closed | -$2.03M | – | 1561 |
|
|
2024
Q4 | $1.82M | Buy |
19,692
+7,686
| +64% | +$692K | ﹤0.01% | 873 |
|
|
2024
Q3 | $1.01M | Sell |
12,006
-79,408
| -87% | -$6.06M | ﹤0.01% | 959 |
|
|
2024
Q2 | $6.27M | Buy |
91,414
+38,961
| +74% | +$2.6M | 0.02% | 403 |
|
|
2024
Q1 | $3.84M | Buy |
52,453
+40,015
| +322% | +$3.08M | 0.01% | 537 |
|
|
2023
Q4 | $1.01M | Sell |
12,438
-21,217
| -63% | -$1.65M | ﹤0.01% | 1048 |
|
|
2023
Q3 | $2.52M | Buy |
33,655
+14,052
| +72% | +$1.08M | 0.01% | 647 |
|
|
2023
Q2 | $1.51M | Buy |
19,603
+19,600
| +653,333% | +$1.56M | 0.01% | 722 |
|
|
2023
Q1 | $249 | Sell |
3
-3,033
| -100% | -$251K | ﹤0.01% | 1532 |
|
|
2022
Q4 | $261K | Sell |
3,036
-125,127
| -98% | -$9.91M | ﹤0.01% | 1247 |
|
|
2022
Q3 | $7.91M | Buy |
128,163
+47,609
| +59% | +$3M | 0.05% | 283 |
|
|
2022
Q2 | $4.98M | Sell |
80,554
-153,843
| -66% | -$9.52M | 0.02% | 414 |
|
|
2022
Q1 | $13.9M | Buy |
234,397
+233,710
| +34,019% | +$14.9M | 0.04% | 350 |
|
|
2021
Q4 | $50K | Sell |
687
-104,063
| -99% | -$7.17M | ﹤0.01% | 1688 |
|
|
2021
Q3 | $7.32M | Buy |
+104,750
| New | +$7.36M | 0.01% | 723 |
|
|
2021
Q1 | – | Sell |
-185,679
| Closed | -$12M | – | 1771 |
|
|
2020
Q4 | $10.8M | Buy |
185,679
+9,256
| +5% | +$559K | 0.04% | 387 |
|
|
2020
Q3 | $11.1M | Buy |
+176,423
| New | +$12.2M | 0.06% | 294 |
|
|
2020
Q1 | – | Sell |
-50,158
| Closed | -$3.47M | – | 1238 |
|
|
2019
Q4 | $3.26M | Buy |
50,158
+13,132
| +35% | +$855K | 0.02% | 693 |
|
|
2019
Q3 | $2.35M | Buy |
37,026
+733
| +2% | +$47.9K | 0.02% | 685 |
|
|
2019
Q2 | $2.45M | Sell |
36,293
-16,980
| -32% | -$1.12M | 0.02% | 683 |
|
|
2019
Q1 | $3.46M | Buy |
53,273
+17,688
| +50% | +$1.18M | 0.03% | 450 |
|
|
2018
Q4 | $2.23M | Buy |
35,585
+14,808
| +71% | +$1.04M | 0.03% | 413 |
|
|
2018
Q3 | $1.6M | Sell |
20,777
-4,035
| -16% | -$305K | 0.02% | 481 |
|
|
2018
Q2 | $1.76M | Buy |
24,812
+23,066
| +1,321% | +$1.63M | 0.03% | 301 |
|
|
2018
Q1 | $132K | Sell |
1,746
-1,529
| -47% | -$122K | ﹤0.01% | 322 |
|
|
2017
Q4 | $234K | Buy |
+3,275
| New | +$249K | 0.01% | 411 |
|
|
2017
Q3 | – | Sell |
-18,283
| Closed | -$1.4M | – | 616 |
|
|
2017
Q2 | $1.29M | Sell |
18,283
-4,240
| -19% | -$282K | 0.04% | 298 |
|
|
2017
Q1 | $1.53M | Sell |
22,523
-44,172
| -66% | -$3.11M | 0.04% | 341 |
|
|
2016
Q4 | $4.78M | Buy |
66,695
+50,595
| +314% | +$3.76M | 0.15% | 134 |
|
|
2016
Q3 | $1.27M | Buy |
+16,100
| New | +$1.31M | 0.03% | 333 |
|
|
2016
Q1 | – | Sell |
-13,000
| Closed | -$1.31M | – | 688 |
|
|
2015
Q4 | $1.31M | Sell |
13,000
-7,000
| -35% | -$728K | 0.04% | 215 |
|
|
2015
Q3 | $1.96M | Buy |
20,000
+10,000
| +100% | +$1.11M | 0.05% | 187 |
|
|
2015
Q2 | $1.17M | Buy |
+10,000
| New | +$1.09M | 0.02% | 247 |
|
|
2014
Q2 | – | Sell |
-20,100
| Closed | -$1.56M | – | 424 |
|
|
2014
Q1 | $1.42M | Buy |
+20,100
| New | +$1.58M | 0.02% | 276 |
|
Other funds holding GILD
VCM
VPM
Capstone Investment Advisors's GILD Position: Q1 2026 in Review
Capstone Investment Advisors opened a new position in Gilead Sciences (GILD) in Q1 2026: 6,254 shares worth $872K. The stake represents ﹤0.01% of the portfolio and ranks #906 among its holdings. This is a return to the name: Capstone Investment Advisors previously reported a position in GILD as recently as Q3 2025.
Capstone Investment Advisors first reported a position in GILD in Q1 2014 and has held it in 36 quarters since. The position peaked at $13.9M in Q1 2022. 2,318 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Capstone Investment Advisors held 6,254 shares of Gilead Sciences worth $872K as of Q1 2026.
- Gilead Sciences was a new Capstone Investment Advisors position in Q1 2026.
- Gilead Sciences made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q1 2026, its #906 holding.
- Capstone Investment Advisors first reported a position in Gilead Sciences in Q1 2014 and has held it in 36 quarters since.
- Capstone Investment Advisors's Gilead Sciences position peaked at $13.9M in Q1 2022.
- 2,318 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Capstone Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.